ACP
CRDF icon

Acuta Capital Partners’s Cardiff Oncology CRDF Stock Holding History

Acuta Capital Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-305,900
Closed -$4.34M – 54
2020
Q3 		$4.34M Sell
305,900
-101,600
-25% -$671K 1.18% 28
2020
Q2 		$2.04M Buy
+407,500
New +$834K 0.59% 42

Other funds holding CRDF

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Acuta Capital Partners's CRDF Position: Q4 2020 in Review

Acuta Capital Partners sold out of Cardiff Oncology (CRDF) in Q4 2020, closing a stake of 305,900 shares — an estimated $4.34M sold.

Acuta Capital Partners first reported a position in CRDF in Q2 2020 and held it in 2 quarters. The position peaked at $4.34M in Q3 2020. 82 funds tracked by Wall St. Rank hold CRDF as of Q4 2020.

  • Acuta Capital Partners reported no remaining Cardiff Oncology position as of Q4 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 305,900 Cardiff Oncology shares in Q4 2020, an estimated $4.34M.
  • Acuta Capital Partners first reported a position in Cardiff Oncology in Q2 2020 and held it in 2 quarters.
  • Acuta Capital Partners's Cardiff Oncology position peaked at $4.34M in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2020.

Based on Acuta Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.